These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 31018160

  • 1. Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: A retrospective cohort study.
    Song W, Jeong JY, Jeon HG, Seo SI, Jeon SS, Choi HY, Lee HM, Sung HH.
    Int J Surg; 2019 Jun; 66():12-17. PubMed ID: 31018160
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
    Nakagawa T, Komemushi Y, Kawai T, Otsuka M, Miyakawa J, Uemura Y, Kanatani A, Taguchi S, Naito A, Suzuki M, Nishimatsu H, Hirano Y, Tanaka Y, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y.
    World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
    Shigeta K, Matsumoto K, Ogihara K, Murakami T, Anno T, Umeda K, Izawa M, Baba Y, Sanjo T, Shojo K, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Arita Y, Akita H, Jinzaki M, Kikuchi E, Oya M.
    Urol Oncol; 2022 Mar; 40(3):105.e19-105.e26. PubMed ID: 34454822
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma.
    Li H, Zhou J, Chen R, Zhu J, Wang J, Wen R.
    Urol Oncol; 2023 Aug; 41(8):356.e1-356.e9. PubMed ID: 37331821
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic Impact of Preoperative Albumin-Globulin Ratio on Oncologic Outcomes in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy.
    Xu H, Tan P, Ai J, Huang Y, Lin T, Yang L, Wei Q.
    Clin Genitourin Cancer; 2018 Oct; 16(5):e1059-e1068. PubMed ID: 29980449
    [Abstract] [Full Text] [Related]

  • 9. Prognostic Role of Neutrophil-to-lymphocyte Ratio-based Markers During Pre- and Postadjuvant Chemotherapy in Patients With Advanced Urothelial Carcinoma of Upper Urinary Tract.
    Kang M, Jeong CW, Kwak C, Kim HH, Ku JH.
    Clin Genitourin Cancer; 2017 Aug; 15(4):e633-e643. PubMed ID: 28174011
    [Abstract] [Full Text] [Related]

  • 10. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome.
    Yafi FA, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Lacombe L, Chin J, So A, Lattouf JB, Bell D, Fradet Y, Saad F, Matsumoto E, Drachenberg D, Cagiannos I, Kassouf W.
    Urol Oncol; 2014 Jan; 32(1):31.e17-24. PubMed ID: 23428535
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity.
    Luo Y, Feng B, Wei D, Han Y, Li M, Zhao J, Lin Y, Hou Z, Jiang Y.
    Sci Rep; 2020 Oct 19; 10(1):17674. PubMed ID: 33077839
    [Abstract] [Full Text] [Related]

  • 12. Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study.
    Veeratterapillay R, Geraghty R, Pandian R, Roy C, Stenhouse G, Bird C, Soomro N, Paez E, Rogers A, Johnson M, Page T, Rix D, Thomas D, Rai BP.
    BJU Int; 2022 Jun 19; 129(6):744-751. PubMed ID: 34726325
    [Abstract] [Full Text] [Related]

  • 13. [Prospective controlled observation ofeffect of adjuvant chemotherapy onsurvival and prognosis ofhigh-risk upper tract urothelial carcinoma patients underwent radical nephroureterectomy].
    Luo Y, Feng BF, Wei DC, Han YL, Li MC, Zhao JH, Lin YH, Li Q, Hou Z, Zhang GY, Jiang YG.
    Zhonghua Yi Xue Za Zhi; 2019 Oct 29; 99(40):3158-3163. PubMed ID: 31694107
    [Abstract] [Full Text] [Related]

  • 14. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.
    Singla N, Christie A, Freifeld Y, Ghandour RA, Woldu SL, Clinton TN, Petros FG, Robyak H, Yeh HC, Fang D, Enikeev D, Bagrodia A, Sagalowsky AI, Lotan Y, Raman JD, Matin SF, Margulis V.
    Urol Oncol; 2020 Dec 29; 38(12):933.e7-933.e12. PubMed ID: 32430254
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma.
    Seisen T, Krasnow RE, Bellmunt J, Rouprêt M, Leow JJ, Lipsitz SR, Vetterlein MW, Preston MA, Hanna N, Kibel AS, Sun M, Choueiri TK, Trinh QD, Chang SL.
    J Clin Oncol; 2017 Mar 10; 35(8):852-860. PubMed ID: 28045620
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
    Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, Chakraborti P, Donovan JL, Elliott PA, French A, Jagdev S, Jenkins B, Keeley FX, Kockelbergh R, Powles T, Wagstaff J, Wilson C, Todd R, Lewis R, Hall E.
    Lancet; 2020 Apr 18; 395(10232):1268-1277. PubMed ID: 32145825
    [Abstract] [Full Text] [Related]

  • 17. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martínez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V.
    Eur Urol; 2012 Apr 18; 61(4):818-25. PubMed ID: 22284969
    [Abstract] [Full Text] [Related]

  • 18. Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study.
    Kang HW, Seo SP, Kim WT, Kim YJ, Yun SJ, Lee SC, Choi YD, Ha YS, Kim TH, Kwon TG, Byun SS, Jeh SU, Kim WJ.
    J Korean Med Sci; 2017 Feb 18; 32(2):335-342. PubMed ID: 28049247
    [Abstract] [Full Text] [Related]

  • 19. Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
    Zennami K, Sumitomo M, Takahara K, Nukaya T, Takenaka M, Fukaya K, Ichino M, Fukami N, Sasaki H, Kusaka M, Shiroki R.
    BJU Int; 2021 Mar 18; 127(3):332-339. PubMed ID: 32896105
    [Abstract] [Full Text] [Related]

  • 20. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
    Hsieh MC, Chiang PH, Rau KM, Chen YY, Su YL, Huang CH.
    Urol Oncol; 2015 Nov 18; 33(11):495.e9-495.e14. PubMed ID: 26254698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.